However, Eli Lilly’s weight loss drugs have demonstrated superior efficacy, challenging Novo Nordisk’s market dominance. Novo’s stock has fallen nearly 20% year to date, compared to the ...

According to FactSet, Novo Nordisk has a nearly 65% grip on the market vs. just 34% for Eli Lilly. The diabetes space is more competitive, though, with Lilly owning about 41% compared to 38% for Novo.

Learn More » Zepbound conclusively beats Wegovy In December, Eli Lilly released top-line data from a phase 3 clinical trial that pitted its weight loss medicine Zepbound with Novo Nordisk's Wegovy.

Eli Lilly can still rise in value from where it is, but I think there's far more room for Novo Nordisk to rise higher in both the short term and the long term, given its more modest price tag. 3.

Numerous exchange-traded funds (ETFs) offer exposure to Novo Nordisk, Eli Lilly, and Viking Therapeutics. Amplify Weight Loss Drug & Treatment ETF (THNR 0.75%) and Roundhill GLP-1 & Weight Loss ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

A cautious culture cost Novo its obesity lead Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly.

That might not exactly be peak diversification, but Eli Lilly fares better than its eternal rival, Novo Nordisk, in this department. Furthermore, the company's newer products also feature several ...

Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger. Over the past six months, Eli Lilly has ...